Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer

Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer
Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, unilateral prostate cancer, without the common side effects of traditional approaches, a small study suggests. The procedure was well tolerated, and 80% of the men were free of clinically significant disease at six and 18 months post-treatment, its researchers reported. Still, larger studies are needed to better assess the therapeutic potential of partial cryotherapy in this patient population, they added. The study, “18-Month Outcomes of Hemi-Gland Cryoablation Of Prostate Cancer Evaluated By MRI-Guided Biopsy,” was published in the Journal of Urology. These findings were to be presented at the American Urological Association 2020 Annual Meeting, which was canceled due to the COVID-19 pandemic. Cryotherapy, also known as cryoablation, involves ultrasound-guided delivery of very cold temperatures to freeze and kill prostate cancer cells. This approach was the first focal therapy for prostate cancer, meaning it targets the cancerous p
Subscribe or to access all post and page content.